Table 1

Main characteristics of selected studies

Study no. (ref)	Patients no. (OC vs BGD)	Company/platform of HE4 assay	Company/platform of CA-125 assay	Enrolling centre	Study design	Data presentation
1 (18)	66 vs 257	Abbott/Architect	Abbott/Architect	G	CS	Binary data
2 (19)	113* vs 165†	Abbott/Architect	Abbott/Architect	GO	CS	Binary data
3 (20)	125‡ vs 289	Abbott/Architect	Abbott/Architect	G	CC	Binary data
4 (21)	111§ vs 285¶	Abbott/Architect	Abbott/Architect	G	CS	Binary data
5 (22)	34** vs 195	Abbott/Architect	Abbott/Architect	G	PCT	Binary data
6 (23)	52 vs 150	CanAg ELISA	CanAg ELISA	GO	CS	Binary data
7 (24)	96 vs 90	Abbott/Architect— Fujirebio ELISA	Abbott/Architect— Fujirebio ELISA	GO	CS	Means
8 (25)	29 vs 71	Fujirebio ELISA	Fujirebio ELISA	GO	CS	Binary data
9 (26)	161†† vs 228‡‡	Fujirebio ELISA	Fujirebio ELISA	GO	PCT	Binary data
10 (27)	55 vs 49	Fujirebio ELISA	Fujirebio ELISA	G	CC	Binary data
11 (28)	149 vs 350	Luminex Multiplexed ELISA	Luminex Multiplexed ELISA	GO	PCT	Binary data
12 (29)	37 vs 50	CanAg ELISA	CanAg ELISA	G	CS	Binary data
13 (30)	41§§ vs 24	Fujirebio ELISA	Roche Diagnostics/Cobas e411	G	CC	Binary data
14 (31)	32 vs 86	Fujirebio ELISA	Radim RIA	GO	CC	Binary data
15 (32)	227¶¶ vs 158***	Luminex Multiplexed ELISA	Luminex Multiplexed ELISA	G	CS	Binary data
16 (33)	14 vs 69†††	Fujirebio ELISA	Fujirebio ELISA	G	CS	Means

*26 pre- and 87 post-menopause.
†69 pre- and 96 post-menopause.
‡24 early (International Federation of Gynaecology and Obstetrics (FIGO) stage I/II) and 101 late (FIGO stage III/IV).
§27 pre- and 84 post-menopause.
¶226 pre- and 59 post-menopause.
**Pre-menopausal women only.
††42 pre- and 119 post-menopause.
‡‡142 pre- and 86 post-menopause.
§§13 early (FIGO stage I/II) and 28 late (FIGO stage III/IV).
¶¶58 pre- and 169 post-menopause (63 early (FIGO stage I/II) and 106 late (FIGO stage III/IV)).
***18 pre- and 140 post-menopause.
†††Ovarian endometriosis only.
BGD, benign gynaecological disease; CC, case–control study; CS, cross-sectional study; OC, ovarian cancer; G, gynaecology; GO, gynaecology–oncology; HE4, human epididymis protein 4; PCT, prospective clinical trial; RIA, radioimmunoassay.